PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

L.-T. Chen,J. Siveke,A. Wang-Gillam, R. Hubner,S. Pant, T. Dragovich,V. Chung, D. Chang, P. Ross,P. Cooray,N. Tebbutt,F. Franke, B. Belanger, N. Dhindsa,F. de Jong, K. Mamlouk,D. Von Hoff

Annals of Oncology(2016)

引用 1|浏览34
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要